Michele Marchioni1,2, Marco Bandini3,4, Raisa S Pompe3,5, Zhe Tian3, Tristan Martel3,6, Anil Kapoor7, Luca Cindolo8, Francesco Berardinelli8, Alberto Briganti4, Shahrokh F Shariat9, Luigi Schips8, Pierre I Karakiewicz3,6. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. mic.marchioni@gmail.com. 2. Department of Urology, SS Annunziata Hospital, "G.D'Annunzio" University of Chieti, Chieti, Italy. mic.marchioni@gmail.com. 3. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. 4. Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. 5. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 6. Department of Urology, University of Montreal Health Centre, Montreal, QC, Canada. 7. Division of Urology, McMaster University, Hamilton, ON, Canada. 8. Department of Urology, ASL Abruzzo 2, Chieti, Italy. 9. Department of Urology, Medical University of Vienna, Vienna, Austria.
Abstract
OBJECTIVE: To examine the effect of diagnosis year, defined as contemporary (2010-2014), intermediate (2006-2009) and historical (2001-2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within Surveillance, Epidemiology, and End Results registry (2001-2014), we identified patients with mRCC. Cumulative incidence and competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality. Finally, we performed subgroup analyses according to histological subtype: clear-cell mRCC (ccmRCC) versus non-ccmRCC. RESULTS: We identified 15,444 patients with mRCC. Of those, 41.0, 28.7 and 30.3% were diagnosed, respectively, in the contemporary, intermediate and historical years. Of all, 47.1, 5.3 and 47.6% were, respectively, ccmRCC, non-ccmRCC and other mRCC histological variants [sarcomatoid mRCC, cyst-associated mRCC, collecting duct carcinoma and mRCC not otherwise specified (NOS)]. Overall, 24-month CSM rates were, respectively, 61.0, 63.7 and 67.3% in contemporary, intermediate and historical patients. In all patients, multivariable CRR models exhibited higher CSM in intermediate (HR 1.11; p < 0.001) and historical patients (HR 1.24; p < 0.001) than in contemporary patients. Multivariable CRR models focusing on ccmRCC yielded virtually the same results. However, multivariable CRR models focusing on non-ccmRCC showed no CSM differences according to diagnosis year (all p ≥ 0.3). CONCLUSION: The introduction of new therapeutic agents resulted in CSM-free survival improvement over study time. However, this effect exclusively applies to patients with ccmRCC, but not to those with non-ccmRCC. This observation is in agreement with established efficacy of systemic therapies for ccmRCC, but lesser efficacy of these agents for non-ccmRCC.
OBJECTIVE: To examine the effect of diagnosis year, defined as contemporary (2010-2014), intermediate (2006-2009) and historical (2001-2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within Surveillance, Epidemiology, and End Results registry (2001-2014), we identified patients with mRCC. Cumulative incidence and competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality. Finally, we performed subgroup analyses according to histological subtype: clear-cell mRCC (ccmRCC) versus non-ccmRCC. RESULTS: We identified 15,444 patients with mRCC. Of those, 41.0, 28.7 and 30.3% were diagnosed, respectively, in the contemporary, intermediate and historical years. Of all, 47.1, 5.3 and 47.6% were, respectively, ccmRCC, non-ccmRCC and other mRCC histological variants [sarcomatoid mRCC, cyst-associated mRCC, collecting duct carcinoma and mRCC not otherwise specified (NOS)]. Overall, 24-month CSM rates were, respectively, 61.0, 63.7 and 67.3% in contemporary, intermediate and historical patients. In all patients, multivariable CRR models exhibited higher CSM in intermediate (HR 1.11; p < 0.001) and historical patients (HR 1.24; p < 0.001) than in contemporary patients. Multivariable CRR models focusing on ccmRCC yielded virtually the same results. However, multivariable CRR models focusing on non-ccmRCC showed no CSM differences according to diagnosis year (all p ≥ 0.3). CONCLUSION: The introduction of new therapeutic agents resulted in CSM-free survival improvement over study time. However, this effect exclusively applies to patients with ccmRCC, but not to those with non-ccmRCC. This observation is in agreement with established efficacy of systemic therapies for ccmRCC, but lesser efficacy of these agents for non-ccmRCC.
Authors: Robert J Motzer; Bernard Escudier; Stephane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Liam C Macleod; Scott S Tykodi; Sarah K Holt; Jonathan L Wright; Daniel W Lin; Maria S Tretiakova; Lawrence D True; John L Gore Journal: Urology Date: 2015-07-18 Impact factor: 2.649
Authors: Luca Cindolo; Paolo Chiodini; Sabine Brookman-May; Ottavio De Cobelli; Matthias May; Stefano Squillacciotti; Cosimo De Nunzio; Andrea Tubaro; Ioan Coman; Bodgan Feciche; Michael Truss; Manfred P Wirth; Orietta Dalpiaz; Thomas F Chromecki; Shahrock F Shariat; Manuel Sanchez-Chapado; Maria del Carmen Santiago Martin; Bernardo Rocco; Luigi Salzano; Giuseppe Lotrecchiano; Francesco Berardinelli; Luigi Schips Journal: BJU Int Date: 2013-03-07 Impact factor: 5.588
Authors: Robert J Motzer; Bernard Escudier; Piotr Tomczak; Thomas E Hutson; M Dror Michaelson; Sylvie Negrier; Stephane Oudard; Martin E Gore; Jamal Tarazi; Subramanian Hariharan; Connie Chen; Brad Rosbrook; Sinil Kim; Brian I Rini Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Marco Bandini; Raisa S Pompe; Michele Marchioni; Emanuele Zaffuto; Giorgio Gandaglia; Nicola Fossati; Luca Cindolo; Francesco Montorsi; Alberto Briganti; Fred Saad; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2017-11-11 Impact factor: 2.370
Authors: Gabriele Sorce; Benedikt Hoeh; Lukas Hohenhorst; Andrea Panunzio; Stefano Tappero; Nancy Nimer; Zhe Tian; Alessandro Larcher; Umberto Capitanio; Derya Tilki; Carlo Terrone; Felix K H Chun; Alessandro Antonelli; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2022-10-12 Impact factor: 3.661
Authors: Felix Preisser; Elio Mazzone; Sophie Knipper; Sebastiano Nazzani; Marco Bandini; Shahrokh F Shariat; Michele Marchioni; Zhe Tian; Fred Saad; Daniel Taussky; Alberto Briganti; Hartwig Huland; Markus Graefen; Derya Tilki; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2019-11-29 Impact factor: 1.862
Authors: Sherrie L Aspinall; Xinhua Zhao; Mark C Geraci; Chester B Good; Francesca E Cunningham; Bernadette B Heron; Daniel Becker; Steve Lee; Vinay Prasad Journal: Cancer Med Date: 2019-09-19 Impact factor: 4.452
Authors: Michael R Harrison; Brian A Costello; Nrupen A Bhavsar; Ulka Vaishampayan; Sumanta K Pal; Yousef Zakharia; Heather S L Jim; Mayer N Fishman; Ana M Molina; Christos E Kyriakopoulos; Che-Kai Tsao; Leonard J Appleman; Benjamin A Gartrell; Arif Hussain; Walter M Stadler; Neeraj Agarwal; Russell K Pachynski; Thomas E Hutson; Hans J Hammers; Christopher W Ryan; Brant A Inman; Jack Mardekian; Azah Borham; Daniel J George Journal: Cancer Date: 2021-03-25 Impact factor: 6.860